Pfizer Inc.

40.15-0.5300-1.30%Vol 21.29M1Y Perf 20.48%
Jun 11th, 2021 16:02 DELAYED
BID40.13 ASK40.15
Open40.66 Previous Close40.68
Pre-Market- After-Market40.16
 - -  0.01 0.02%
Target Price
42.29 
Analyst Rating
Moderate Buy 2.00
Potential %
5.33 
Finscreener Ranking
★★     46.44
Insiders Trans % 3/6/12 mo.
-100/-100/54 
Value Ranking
★★★     52.66
Insiders Value % 3/6/12 mo.
-100/-100/-78 
Growth Ranking
★★★     53.70
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-76 
Income Ranking
★★★+     49.93
Market Cap224.75B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
74.46 
Earnings Date
27th Jul 2021

Today's Price Range

39.9540.67

52W Range

31.6143.08

5 Year PE Ratio Range

8.9031.90

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
2.55%
1 Month
1.16%
3 Months
14.91%
6 Months
-2.36%
1 Year
20.48%
3 Years
10.61%
5 Years
14.72%
10 Years
134.22%

TickerPriceChg.Chg.%
PFE40.15-0.5300-1.30
AAPL127.351.24000.98
GOOG2 513.93-7.6700-0.30
MSFT257.890.65000.25
XOM62.17-0.5800-0.92
WFC45.680.59001.31
JNJ164.96-2.1200-1.27
FB331.26-1.2000-0.36
GE13.690.06000.44
JPM160.29-0.1100-0.07
Financial StrengthValueIndustryS&P 500US Markets
1.00
1.50
0.33
0.56
8.40
Leverage Ratio 2.60
ProfitabilityValueIndustryS&P 500US Markets
76.40
25.30
35.70
9.40
25.15
RevenueValueIndustryS&P 500US Markets
44.46B
7.94
-6.71
-3.20
DividendsValueIndustryS&P 500US Markets
4.00
1.56
4.97
5.78
Payout ratio122.00
Earnings HistoryEstimateReportedSurprise %
Q01 20210.790.9317.72
Q04 20200.460.42-8.70
Q03 20200.700.722.86
Q02 20200.640.7821.88
Q01 20200.710.8012.68
Q04 20190.570.55-3.51
Q03 20190.630.7519.05
Q02 20190.770.803.90
Earnings Per EndEstimateRevision %Trend
6/2021 QR0.9816.67Positive
9/2021 QR0.969.09Positive
12/2021 FY3.6914.60Positive
12/2022 FY3.248.36Positive
Next Report Date27th Jul 2021
Estimated EPS Next Report0.98
Estimates Count5
EPS Growth Next 5 Years %7.60
Volume Overview
Volume21.29M
Shares Outstanding5.60B
Trades Count98.42K
Dollar Volume1.60B
Avg. Volume30.57M
Avg. Weekly Volume26.31M
Avg. Monthly Volume22.45M
Avg. Quarterly Volume27.36M

Pfizer Inc. (NYSE: PFE) stock closed at 40.15 per share at the end of the most recent trading day (a -1.3% change compared to the prior day closing price) with a volume of 21.38M shares and market capitalization of 224.75B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 78500 people. Pfizer Inc. CEO is Albert Bourla.

The one-year performance of Pfizer Inc. stock is 20.48%, while year-to-date (YTD) performance is 9.07%. PFE stock has a five-year performance of 14.72%. Its 52-week range is between 31.61 and 43.08, which gives PFE stock a 52-week price range ratio of 74.46%

Pfizer Inc. currently has a PE ratio of 19.90, a price-to-book (PB) ratio of 3.19, a price-to-sale (PS) ratio of 4.91, a price to cashflow ratio of 14.00, a PEG ratio of 2.32, a ROA of 6.63%, a ROC of 11.04% and a ROE of 16.17%. The company’s profit margin is 25.15%, its EBITDA margin is 35.70%, and its revenue ttm is $44.46 Billion , which makes it $7.94 revenue per share.

Of the last four earnings reports from Pfizer Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.98 for the next earnings report. Pfizer Inc.’s next earnings report date is 27th Jul 2021.

The consensus rating of Wall Street analysts for Pfizer Inc. is Moderate Buy (2), with a target price of $42.29, which is +5.33% compared to the current price. The earnings rating for Pfizer Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Pfizer Inc. has a dividend yield of 4.00% with a dividend per share of $1.56 and a payout ratio of 122.00%.

Pfizer Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 6.10, ATR14 : 0.66, CCI20 : 93.74, Chaikin Money Flow : -0.18, MACD : 0.28, Money Flow Index : 37.87, ROC : 2.08, RSI : 59.22, STOCH (14,3) : 74.67, STOCH RSI : 0.64, UO : 54.28, Williams %R : -25.33), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Pfizer Inc. in the last 12-months were: Albert Bourla (Option Excercise at a value of $4 939 038), Albert Bourla (Sold 132 508 shares of value $5 557 385 ), Alexander R. Mackenzie (Option Excercise at a value of $666 879), Angela Hwang (Option Excercise at a value of $740 235), Douglas M. Lankler (Option Excercise at a value of $3 490 011), Frank A. D'Amelio (Option Excercise at a value of $7 153 459), Jennifer B. Damico (Option Excercise at a value of $506 551), Jennifer B. Damico (Sold 2 500 shares of value $102 050 ), John Douglas Young (Option Excercise at a value of $6 631 229), Payal Sahni (Option Excercise at a value of $228 488), Rady A. Johnson (Option Excercise at a value of $1 424 429), Ronald E. Blaylock (Buy at a value of $924 790), Sally Susman (Option Excercise at a value of $3 476 299), Sally Susman (Sold 43 662 shares of value $1 831 184 ), William R. Carapezzi (Option Excercise at a value of $1 105 201)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (44.44 %)
3 (37.50 %)
4 (44.44 %)
Moderate Buy
1 (11.11 %)
1 (12.50 %)
1 (11.11 %)
Hold
4 (44.44 %)
4 (50.00 %)
4 (44.44 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.13
Moderate Buy
2.00

Pfizer Inc.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

CEO: Albert Bourla

Telephone: +1 212 733-2323

Address: 235 East 42nd Street, New York 10017, NY, US

Number of employees: 78 500

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

53%47%

Bearish Bullish

53%47%

News

Stocktwits